J J Lin1, S V Liu2, C E McCoach3, V W Zhu4, A C Tan5, S Yoda1, J Peterson1, A Do1, K Prutisto-Chang1, I Dagogo-Jack1, L V Sequist1, L J Wirth1, J K Lennerz6, A N Hata1, M Mino-Kenudson6, V Nardi6, S-H I Ou4, D S-W Tan5, J F Gainor7. 1. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. 2. Department of Medicine, Georgetown University, Washington, USA. 3. Department of Medicine, University of California San Francisco, San Francisco, USA. 4. Department of Medicine, University of California, Irvine, USA. 5. Division of Medical Oncology, National Cancer Centre Singapore, Singapore. 6. Harvard Medical School, Boston, USA; Department of Pathology, Massachusetts General Hospital, Boston, USA. 7. Department of Medicine, Massachusetts General Hospital Cancer Center, Boston, USA; Harvard Medical School, Boston, USA. Electronic address: jgainor@mgh.harvard.edu.
Abstract
BACKGROUND: Rearranged during transfection (RET) gene fusions are a validated target in non-small-cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity and safety profiles in advanced RET fusion-positive NSCLC, and both have received approval by the US Food and Drug Administration for this indication. Insights into mechanisms of resistance to selective RET inhibitors remain limited. PATIENTS AND METHODS: This study was performed at five institutions. Tissue and/or cell-free DNA was obtained from patients with RET fusion-positive NSCLC after treatment with selpercatinib or pralsetinib and assessed by next-generation sequencing (NGS) or MET FISH. RESULTS: We analyzed a total of 23 post-treatment tissue and/or plasma biopsies from 18 RET fusion-positive patients who received an RET-selective inhibitor (selpercatinib, n = 10; pralsetinib, n = 7; pralsetinib followed by selpercatinib, n = 1, with biopsy after each inhibitor). Three cases had paired tissue and plasma samples, of which one also had two serial resistant tissue specimens. The median progression-free survival on RET inhibitors was 6.3 months [95% confidence interval 3.6-10.8 months]. Acquired RET mutations were identified in two cases (10%), both affecting the RET G810 residue in the kinase solvent front. Three resistant cases (15%) harbored acquired MET amplification without concurrent RET resistance mutations, and one specimen had acquired KRAS amplification. No other canonical driver alterations were identified by NGS. Among 16 resistant tumor specimens, none had evidence of squamous or small-cell histologic transformation. CONCLUSIONS: RET solvent front mutations are a recurrent mechanism of RET inhibitor resistance, although they occurred at a relatively low frequency. The majority of resistance to selective RET inhibition may be driven by RET-independent resistance such as acquired MET or KRAS amplification. Next-generation RET inhibitors with potency against RET resistance mutations and combination strategies are needed to effectively overcome resistance in these patients.
BACKGROUND: Rearranged during transfection (RET) gene fusions are a validated target in non-small-cell lung cancer (NSCLC). RET-selective inhibitors selpercatinib (LOXO-292) and pralsetinib (BLU-667) recently demonstrated favorable antitumor activity and safety profiles in advanced RET fusion-positive NSCLC, and both have received approval by the US Food and Drug Administration for this indication. Insights into mechanisms of resistance to selective RET inhibitors remain limited. PATIENTS AND METHODS: This study was performed at five institutions. Tissue and/or cell-free DNA was obtained from patients with RET fusion-positive NSCLC after treatment with selpercatinib or pralsetinib and assessed by next-generation sequencing (NGS) or MET FISH. RESULTS: We analyzed a total of 23 post-treatment tissue and/or plasma biopsies from 18 RET fusion-positive patients who received an RET-selective inhibitor (selpercatinib, n = 10; pralsetinib, n = 7; pralsetinib followed by selpercatinib, n = 1, with biopsy after each inhibitor). Three cases had paired tissue and plasma samples, of which one also had two serial resistant tissue specimens. The median progression-free survival on RET inhibitors was 6.3 months [95% confidence interval 3.6-10.8 months]. Acquired RET mutations were identified in two cases (10%), both affecting the RET G810 residue in the kinase solvent front. Three resistant cases (15%) harbored acquired MET amplification without concurrent RET resistance mutations, and one specimen had acquired KRAS amplification. No other canonical driver alterations were identified by NGS. Among 16 resistant tumor specimens, none had evidence of squamous or small-cell histologic transformation. CONCLUSIONS: RET solvent front mutations are a recurrent mechanism of RET inhibitor resistance, although they occurred at a relatively low frequency. The majority of resistance to selective RET inhibition may be driven by RET-independent resistance such as acquired MET or KRAS amplification. Next-generation RET inhibitors with potency against RET resistance mutations and combination strategies are needed to effectively overcome resistance in these patients.
Authors: Vivek Subbiah; Justin F Gainor; Rami Rahal; Jason D Brubaker; Joseph L Kim; Michelle Maynard; Wei Hu; Qiongfang Cao; Michael P Sheets; Douglas Wilson; Kevin J Wilson; Lucian DiPietro; Paul Fleming; Michael Palmer; Mimi I Hu; Lori Wirth; Marcia S Brose; Sai-Hong Ignatius Ou; Matthew Taylor; Elena Garralda; Stephen Miller; Beni Wolf; Christoph Lengauer; Timothy Guzi; Erica K Evans Journal: Cancer Discov Date: 2018-04-15 Impact factor: 39.397
Authors: Doron Lipson; Marzia Capelletti; Roman Yelensky; Geoff Otto; Alex Parker; Mirna Jarosz; John A Curran; Sohail Balasubramanian; Troy Bloom; Kristina W Brennan; Amy Donahue; Sean R Downing; Garrett M Frampton; Lazaro Garcia; Frank Juhn; Kathy C Mitchell; Emily White; Jared White; Zac Zwirko; Tamar Peretz; Hovav Nechushtan; Lior Soussan-Gutman; Jhingook Kim; Hidefumi Sasaki; Hyeong Ryul Kim; Seung-il Park; Dalia Ercan; Christine E Sheehan; Jeffrey S Ross; Maureen T Cronin; Pasi A Jänne; Philip J Stephens Journal: Nat Med Date: 2012-02-12 Impact factor: 53.440
Authors: Alexander Drilon; Siqing Fu; Manish R Patel; Marwan Fakih; Ding Wang; Anthony J Olszanski; Daniel Morgensztern; Stephen V Liu; Byoung Chul Cho; Lyudmila Bazhenova; Cristina P Rodriguez; Robert C Doebele; Antoinette Wozniak; Karen L Reckamp; Tara Seery; Petros Nikolinakos; Zheyi Hu; Jennifer W Oliver; Denise Trone; Katherine McArthur; Rupal Patel; Pratik S Multani; Myung-Ju Ahn Journal: Cancer Discov Date: 2018-11-28 Impact factor: 39.397
Authors: Gorjan Hrustanovic; Victor Olivas; Evangelos Pazarentzos; Asmin Tulpule; Saurabh Asthana; Collin M Blakely; Ross A Okimoto; Luping Lin; Dana S Neel; Amit Sabnis; Jennifer Flanagan; Elton Chan; Marileila Varella-Garcia; Dara L Aisner; Aria Vaishnavi; Sai-Hong I Ou; Eric A Collisson; Eiki Ichihara; Philip C Mack; Christine M Lovly; Niki Karachaliou; Rafael Rosell; Jonathan W Riess; Robert C Doebele; Trever G Bivona Journal: Nat Med Date: 2015-08-24 Impact factor: 53.440
Authors: Mark M Awad; Ryohei Katayama; Michele McTigue; Wei Liu; Ya-Li Deng; Alexei Brooun; Luc Friboulet; Donghui Huang; Matthew D Falk; Sergei Timofeevski; Keith D Wilner; Elizabeth L Lockerman; Tahsin M Khan; Sidra Mahmood; Justin F Gainor; Subba R Digumarthy; James R Stone; Mari Mino-Kenudson; James G Christensen; A John Iafrate; Jeffrey A Engelman; Alice T Shaw Journal: N Engl J Med Date: 2013-06-01 Impact factor: 91.245
Authors: Zofia Piotrowska; Hideko Isozaki; Jochen K Lennerz; Justin F Gainor; Inga T Lennes; Viola W Zhu; Nicolas Marcoux; Mandeep K Banwait; Subba R Digumarthy; Wenjia Su; Satoshi Yoda; Amanda K Riley; Varuna Nangia; Jessica J Lin; Rebecca J Nagy; Richard B Lanman; Dora Dias-Santagata; Mari Mino-Kenudson; A John Iafrate; Rebecca S Heist; Alice T Shaw; Erica K Evans; Corinne Clifford; Sai-Hong I Ou; Beni Wolf; Aaron N Hata; Lecia V Sequist Journal: Cancer Discov Date: 2018-09-26 Impact factor: 39.397
Authors: Jacob J Adashek; Aakash P Desai; Alexander Y Andreev-Drakhlin; Jason Roszik; Gilbert J Cote; Vivek Subbiah Journal: Mol Cancer Ther Date: 2021-09-06 Impact factor: 6.261
Authors: V Subbiah; T Shen; M Tetzlaff; A Weissferdt; L A Byers; T Cascone; A Behrang; F Meric-Bernstam; B H M Mooers; S M Rothenberg; K Ebata; J Wu Journal: Ann Oncol Date: 2021-02-20 Impact factor: 51.769
Authors: Jessica J Lin; Noura J Choudhury; Satoshi Yoda; Aaron N Hata; Alexander Drilon; Justin F Gainor; Viola W Zhu; Ted W Johnson; Ramin Sakhtemani; Ibiayi Dagogo-Jack; Subba R Digumarthy; Charlotte Lee; Andrew Do; Jennifer Peterson; Kylie Prutisto-Chang; Wafa Malik; Harper G Hubbeling; Adam Langenbucher; Adam J Schoenfeld; Christina J Falcon; Jennifer S Temel; Lecia V Sequist; Beow Y Yeap; Jochen K Lennerz; Alice T Shaw; Michael S Lawrence; Sai-Hong Ignatius Ou Journal: Clin Cancer Res Date: 2021-03-08 Impact factor: 12.531